PDF(Pubmed)
Abstract：
Primary lung cancer with pulmonary alveolar proteinosis (PAP) is a rare condition. We present a case of a patient with primary lung cancer with PAP treated with an immune checkpoint inhibitor (ICI). A 62-year-old man was diagnosed with autoimmune PAP 8 years prior to current admission. Lung adenocarcinoma was found in his right lung, and platinum-based chemotherapy was administered, followed by atezolizumab. He experienced disease progression after atezolizumab treatment, whereas ICI-induced pneumonia or exacerbation of PAP did not occur. This indicates that ICI may be safely used in patients with primary lung cancer with PAP.
摘要：
原发性肺癌伴肺泡蛋白沉积症（PAP）是一种罕见的疾病。我们介绍了一例使用免疫检查点抑制剂（ICI）治疗PAP的原发性肺癌患者。一名62岁的男性在入院前8年被诊断为自身免疫性PAP。在他的右肺发现了肺腺癌,并进行了铂类化疗，其次是阿妥珠单抗。他在阿特珠单抗治疗后出现疾病进展，而ICI诱导的肺炎或PAP恶化没有发生。这表明ICI可以安全地用于患有PAP的原发性肺癌患者。
